-+ 0.00%
-+ 0.00%
-+ 0.00%

Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy

PUBT·07/16/2026 21:22:45
Listen to the news
Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy
  • Jasper outlined a merger with Kira Pharmaceuticals in an all-stock deal, paired with a USD 132 million PIPE financing.
  • Fully diluted ownership split: legacy Jasper holders 6.68%, legacy Kira holders 49.86%, PIPE investors 43.46%; shares outstanding about 653,600,000.
  • Legacy Jasper holders to receive a non-transferable CVR tied to up to USD 30 million if a briquilimab PRV is obtained by end-2028.
  • PIPE proceeds earmarked for KP-104 Phase 2 renal data readouts, KP-104 Phase 3 start in PNH, briquilimab pre-BLA work in SCID.
  • Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for a USD 12 million upfront, with additional potential milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.